Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-08-23
2005-08-23
Shameem, Golam M M (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S440000, C548S444000
Reexamination Certificate
active
06933314
ABSTRACT:
Provided are compounds of formula (I)wherein A, Q, W, X, Y, Z, R1to R4, m and n are as defined herein. Compounds of the invention bind to α4integrin receptors and thereby inhibit binding of ligands for α4integrins which is useful for prophylactic and/or therapeutic treatment of diseases and conditions associated with α4integrins or their ligands.
REFERENCES:
patent: 5079260 (1992-01-01), Weitzberg et al.
patent: 5223517 (1993-06-01), Muller et al.
patent: 5272161 (1993-12-01), Niewohner et al.
patent: 5334606 (1994-08-01), MacLeod et al.
patent: 5519043 (1996-05-01), Perumattam
patent: 5773465 (1998-06-01), Gandolfi et al.
patent: 5773646 (1998-06-01), Chandrakumar et al.
patent: 5891899 (1999-04-01), Clark et al.
patent: 5908863 (1999-06-01), Allegretti et al.
patent: 5994351 (1999-11-01), Robinson et al.
patent: 6706753 (2004-03-01), Artis et al.
patent: 327877 (1989-08-01), None
patent: 48054061 (1973-07-01), None
patent: WO 97/01540 (1997-01-01), None
patent: WO 99/10312 (1999-03-01), None
Andrew, H. F., et al., “Nitration of 3-Methylfuoranthene”J. Chem. Soc., Perkins Trans. 1 vol. 6:755-759 (1972).
Butcher et al., “Lymphocyte Homing and Homeostasis”Science272:60-66 (1996).
Cardarelli et al., “Cyclic RGD Peptide Inhibits α4β1 Interaction with Connecting Segment 1 and Vascular Cell Adhesion Molecule”Journal of Biological Chemsitry269:18668-18673 (1994).
Chuluyan et al., “α4-Integrin-dependent emigration of monocytes”Springer Semin. Immunopathology16:391-404 (1995).
Database Crossfire Beilstein ‘Online’, Beilstein Institut zur Forderung der Chemischen Wissenschafte, Frankfurt am Main, DE; Database accession No. 2187180 XP002194815 Abstract; & Campbell, Crombie: Proc. Royal Soc. London, Series A, Mathematical & Physical Sciences, 65:376 (1960-1961) Royal Society of Elices et al., “VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site”Cell60:577-584 (1990).
Fotouhi et al., “Cyclic Thioether Peptide Mimetics as VCAM-VLA-4 Antagonists”Bioorganic&Medicine Chemistry Letters10:1167-1169 (2000).
Hamilton, et al., “Fluorenylalkanoic and Benzoic Acids as Novel Inhibitors of Cell Adhesion Processes in Leukocytes”J. Med. Chem.38:1650-1656 (1995).
Hemler, “VLA proteins in the integrin family: structures, functions, and their role on leukocytes”Annu. Rev. Immunol.8:365-400 (1990).
Hynes, “Integrins: versatility, modulation, and signaling in cell adhesion”Cell69(1):11-25 (1992).
Jackson et al., “Potent α4β1 Peptide Antagonists as Anti-Inflammatory Agents”Journal of Medicinal Chemistry40(21):3359-3368 (Oct. 10, 1997).
Juliano et al., “Adhesion molecules in cancer: the role of integrins”Current Opinion Cell Biology5:812-818 (1993).
Laberge, S. et al., “Role of VLA-4 and LFA-1 in Allergen-Induced Airway Hyperrespnosiveness and Lung Inflammation in the Rat”Am. J. Respir. Crit. Care Med.151:822-829 (1995).
Makarem et al., “Competitive binding of vascular cell adhesion molecule-1 and the HepII/IIICS domain of fibronectin to the intefrin α4β1”Journal of Biological Chemistry269:4005-4011 (1994).
Nakajima et al., “Role of vascular cell adhesion molecule 1/very late activation antigen 4 and intercellular adhesion molecule 1/lymphocyte function-associated antigen 1 interactions in antigen-induced eosinophil and T cell recruitment into the tissue”Journal of Experimental MedicineSharar et al., “The adhesion cascade and anti-adhesion therapy: an overview”Springer Semin. Immunopathology16:359-378 (1995).
Simmons et al., “Vascular cell adhesiin molecular-1 expressed by bone marrow stromal cells mediates the binding of hematopoietic progenitor cells”Blood80:388-395 (1992).
Artis Dean R.
Jackson David Y.
Rawson Thomas E.
Reynolds Mark E.
Stanley Mark S.
Evans David W
Genentech Inc.
Shameem Golam M M
LandOfFree
Integrin receptor inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Integrin receptor inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Integrin receptor inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3470738